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Mental Health Care Delivered to Younger and Older Adults by
Office-Based Physicians Nationally
Donovan T. Maust, MD, MS,*†‡ Helen C. Kales, MD,*†‡ and Frederic C. Blow, PhD*†‡
OBJECTIVES: To compare the provision of mental health
care to older adults with that provided to younger adults.
DESIGN: Analysis of the National Ambulatory Medical
Care Survey.
SETTING: Visits to office-based physicians in the United
States, 2007 to 2010 (n = 100,661 visits).
PARTICIPANTS: Individuals with an outpatient visit
resulting in a mental health diagnosis or treatment, defined
as a visit resulting in a mental disorder diagnosis, at which
a psychotropic medication was prescribed, to a psychia-
trist, or including psychotherapy.
MEASUREMENTS: The number of each type of mental
healthcare visit was estimated according to participant age
(21 to 64, ≥65), along with the percentage this represented
of all office-based care and the annual visit rate per 100
population. Within each visit type, age groups were com-
pared according to clinical and demographic characteristics
such as sex, diagnosed mental illness, and use of psycho-
tropic agents.
RESULTS: Older adults had a smaller proportion than
younger adults of visits with a mental disorder diagnosis
(4.8% vs 9.5%, chi-square = 228.21, P < .001), to a psy-
chiatrist (0.9% vs 4.0%, chi-square = 233.76, P < .001),
and including psychotherapy (0.6% vs 2.3%, chi-
square = 57.65, P < .001). The percentage of older adult
psychotropic visits was slightly smaller than of younger
adult visits (18.1% vs 19.2%, chi-square = 5.33, P = .02).
Older adults had a higher rate of psychotropic visits
(121.4 per 100 population) than younger adults (56.8 per
100 population).
CONCLUSION: Less care of older adults is from psychia-
trists or incorporates psychotherapy. Older adults have a
far higher rate of psychotropic use than younger adults on
a per-population basis. Addressing the mental healthcare
needs of older adults will require care in nonspecialty set-
tings. J Am Geriatr Soc 63:1364–1372, 2015.
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In 2012, the year after the first baby boomers turned 65,the Institute of Medicine released its report The Mental
Health and Substance Use Workforce for Older Adults: In
Whose Hands?1 This report highlights the lack of provid-
ers with expertise necessary to address the mental health
needs of older adults, especially given the burden of men-
tal disorders in this rapidly expanding group.2,3 Efforts to
meet the challenge of delivering mental health care to
older adults should arise from knowledge about the nature
and extent of care they currently receive. Care of mental
disorders in children relative to the adult population, for
example, has received a significant amount of coverage in
the academic and lay press, frequently highlighting the
shortage of specialty mental health providers and increased
use of psychotropic medication,4–7 but with few excep-
tions,8–10 prior analyses of mental health care using
nationally representative data rarely study older adults sep-
arately from the general adult population.
For a variety of reasons, delivery of mental health care
to older adults merits additional attention. Because of
accumulation of medical comorbidity11 as people age and
changes in drug metabolism,12,13 potential drug–disease or
drug–drug interactions that are less likely in younger
adults can complicate pharmacotherapy of mental disor-
ders. The current version of the American Geriatrics Soci-
ety Beers Criteria lists nearly every psychotropic
medication as potentially inappropriate.14 Older adults’
treatment preferences may be different from those of youn-
ger adults,15 and they are less likely to receive treatment in
specialty mental health settings.8,10 Provider concern about
older adults’ cognition and ability to participate in psycho-
therapy may mean fewer referrals than for younger indi-
viduals, although evidence suggests that psychotherapy is
feasible and possibly beneficial even for individuals with
dementia.16,17 In addition, although most older adults
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ultimately have insurance coverage through Medicare, psy-
chiatrists are less likely than other providers to accept
Medicare,18 and older adults may have limited income and
thus be unable or unwilling to pay out of pocket, creating
an additional potential barrier to receiving specialty care.
For purposes of providing care and training providers,
it is important to investigate whether the current under-
standing of outpatient mental health treatment applies to
older adults. With just 1,700 geriatric psychiatrists in prac-
tice,19 access to specialty care will be the exception rather
than the norm as the older adult population continues to
grow. Refining knowledge regarding where older adults
with mental disorders are seen and the nature of the men-
tal health care they receive is critical to understanding
quality and improving delivery. The goal of the current
study was to describe and possibly differentiate the outpa-
tient mental health care of younger and older adults by
building upon recent work.20 Four broad categories of care
were examined: outpatient visits with a mental health
diagnosis, visits at which a psychotropic medication was
prescribed, visits to a psychiatrist, and visits including psy-
chotherapy. What proportion of ambulatory care nation-
wide is dedicated to these types of visits, whether these
visit types differ according to age group, and what demo-
graphic and other clinical characteristics are associated
with mental health care are described.
METHODS
Source of the Data
Data for these analyses were obtained from the National
Ambulatory Medical Care Survey (NAMCS), a national sur-
vey administered by the National Center for Health Statistics
(NCHS; Hyattsville, MD) of the Centers for Disease Control
and Prevention designed to “provide objective, reliable infor-
mation about the provision and use of ambulatory medical
care services in the United States.” This study uses data from
the 2007 to 2010 survey years, the most recent available.
Survey Design
NAMCS is a national probability sample survey of office-
and community health center–based physicians that yielded
125,029 encounters over the 4 study years. Physicians are
sampled from the master files that the American Medical
Association and American Osteopathic Association main-
tain; physicians in the specialties of anesthesiology, pathol-
ogy, and radiology are excluded. In addition, encounters
such as house calls or those to institutional settings (e.g.,
nursing homes) are not included. Each physician is
assigned to a 1-week reporting period, during which time
office staff maintain a log of all visits during the reporting
period. At the end of the week, visits are randomly
selected from this list using a random start and predeter-
mined sampling interval. The physician or office staff
record data for selected visits on a standardized one-page
form. The overall physician response rate over the 4 years
ranged from 58.3% to 62.1%. Adjusting for survey design
elements allows analyses to represent total annual visits to
U.S. office-based physicians.21
Mental Healthcare Visit Classification
To explore how the burden of mental disorders and rates
of mental health treatment in outpatient care vary accord-
ing to age, four types of visits were considered, following
a recent analysis:20 visits resulting in a mental disorder
diagnosis, visits at which a psychotropic medication was
prescribed, visits to a psychiatrist, and visits at which psy-
chotherapy was provided. Mental healthcare visit is used
herein to refer to these four visit types considered together.
For the purposes of these analyses, a mental healthcare
visit does not refer exclusively to a specialty mental health-
care visit.
As part of the information collected at each NAMCS
encounter, up to three diagnoses are recorded using the
International Classification of Diseases, Ninth Revision,
Clinical Modification and the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition. For these
analyses, encounters were then classified as to the presence
or absence of a given condition.22,23 For example, visit
diagnosis codes of 296.2x-296.3x, 296.82, 298.0x,
300.4x, 309.1x, and 311.x defined encounters for a
depressive disorder. Similar criteria were applied to define
visits for psychotic disorders (295.x, 297.x, 298.1x-
298.9x, 299.1x), bipolar disorder (296.0x-296.1x,
296.4x-296.81, 296.89, 301.13), anxiety disorders
(300.0x, 300.2x, 300.3x, 309.21, 309.81, 313.0x), sub-
stance-related disorders (291.x-292.x, 303.x-305.x), and
dementia (290.1 to 290.4, 294.1, 331.0, 331.1, 331.2,
331.82). Last, a category was created for encounters with
any psychiatric diagnosis including dementia (290 to 319,
331.0, 331.1, 331.2, 331.82).
Survey data included up to eight medications pre-
scribed, ordered, supplied, administered, or continued dur-
ing each visit. For these analyses, a visit was classified as a
at which a psychotropic medication was prescribed if any
of the following classes of medications (Appendix 1) was
included in the visit medication list: antidepressants; anxio-
lytics, sedatives, and hypnotics (including benzodiazepines
and nonbenzodiazepine sedatives), hereinafter referred to
as anxiolytics; antipsychotics; mood stabilizers (including
lithium, carbamazepine, valproate and derivatives, lamotri-
gine); and stimulants (including atomoxetine). A visit
could include medications from multiple classes.
NAMCS classifies providers into 15 specialty groups,
which for these analyses were grouped into three catego-
ries: psychiatrist, primary care provider (pediatrics, family
medicine, internal medicine), or other medical specialty.
The survey elicits information regarding the type of ser-
vices and procedures performed during the office encoun-
ter, including a specific item (yes/no) regarding provision
of psychotherapy.
After determining which surveyed visits belonged to
each of the mental health visit categories, the visits were
then stratified according to participant age into two cate-
gories: adult (21 to 64) and older adult (≥65). The visit
categories were not mutually exclusive. For example, a
visit to a general internist for a 55-year-old individual with
diagnoses of diabetes mellitus and major depressive disor-
der who received psychotherapy and was prescribed sertra-
line would be included in three of the four mental health
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care visit categories (all except psychiatrist visit) for the
adult group.
Other Characteristics
Sociodemographic items from the survey used for these
analyses included sex, race and ethnicity (non-Hispanic
white, non-Hispanic black, Hispanic, other), payer (Medi-
care, Medicaid, private insurance, other; categories not
mutually exclusive), urban or rural office location (deter-
mined according to Metropolitan Statistical Area status),
and region of the country (northeast, south, central, west).
Statistical Methods
For each of the four mental healthcare visit types, annual
estimates of office-based visits were determined, and the
estimates for each type were summed over the 4 study
years (2007 to 2010) and then stratified according to par-
ticipant age (younger vs older adult). Analyses were
adjusted for visit weight, clustering within physician prac-
tice, and stratification using survey design elements pro-
vided by NCHS to generate national visit estimates and
corresponding 95% confidence intervals (CIs).21 Survey
years were combined as recommended by NCHS to pro-
duce a more-reliable annual visit rate estimate.22 To gener-
ate population-based visit rates for the four visit types, the
denominator (U.S. population for age group) was obtained
from U.S. Census population estimates for the 4-year study
interval to derive an annual visit rate per 100 population
for each age group.23 Population-based visit rates were
also determined for individual psychotropic class.
After determining the population-based visit rates,
subsequent analyses compared how clinical and demo-
graphic characteristics varied according to age group for
each type of mental healthcare visit. Categorical variables
(e.g., sex) were examined by comparing the proportion of
visits in each age group that corresponded to a given cate-
gory (e.g., 32.3% of older adult visits resulting in a mental
disorder diagnoses were by men, vs 38.8% of adult visits).
Chi-square tests were used to determine associations
between demographic and clinical characteristics and the
four visit types for each age group, with results weighted
to allow national inferences. Analyses were conducted in
Stata 13.1 (Stata Corp., College Station, TX) using two-
sided analyses with a = .05. For population-based visit
rates, which combine NAMCS survey data (numerator)
with U.S. Census information (denominator), statistical
significance was approximated according to nonoverlap of
95% CIs.24
RESULTS
There were 125,029 office visits over the 4 survey years.
When limited to younger and older adults, there were
100,661 visits. Table 1 presents the proportion of total
outpatient visits for each age group in each of the four
mental healthcare visit categories. Mental healthcare visits
were a smaller proportion of the care of older adults than
of younger adults. Of the visit types, the proportion of
psychotropic visits between age groups was most compara-
ble, although slightly lower for older adults (18.1%, 95%
CI = 16.9 to 19.2% vs 19.2%, 95% CI = 18.3 to 20.2%,
chi-square = 5.33, P = .02). The annual population-based
visit rates for each type of mental health visit are presented
in Figure 1 according to age group. The annual psychotro-
pic visit rate (per 100 population) for older adults was
121.4 (95% CI = 106.7 to 136.1), much higher than the
adult rate of 56.8 (95% CI = 50.6 to 62.9). Older adults
had lower rates of psychiatrist and psychotherapy visits.
Mental Disorder Visits
Older women (67.7%) were more likely than younger
women (61.2%) to have a visit with a mental disorder
diagnosis (chi-square2 = 12.86, P < .001), but the propor-
tion of these visits did not vary between age groups
according to race and ethnicity, geographic area, or metro-
politan status (Table 2).
A larger proportion of mental disorder visits for older
adults were to primary care and other specialty providers,
with 19.4% of these visits to a psychiatrist for older
adults, versus 40.1% for younger adults (chi-square =
81.33, P < .001). Older adults had a larger proportion of
visits with a dementia diagnosis, and other diagnoses
accounted for a smaller share of visits than for younger
adults. For mental disorder visits, nearly 75% of partici-
pants received psychotropic medication, which did not
vary according to age group.
Psychotropic Visits
For visits at which a psychotropic medication was pre-
scribed, sex distribution did not differ between age groups.
Older non-Hispanic black adults accounted for a smaller
share of psychotropic visits than their younger adult
Table 1. Mental Healthcare Visits as a Percentage of Total Office-Based Physician Visits for Younger and Older
Adults in the United States from 2007 to 2010
Visit Type
Younger Adults (21–64),
n = 67,653
Older Adults (≥65),
n = 33,008 Chi-Square P-Value
Total office-based visits, n 2,110.280, 000 1,052.840, 000
Mental health visit, %, (95% confidence interval)
Mental disorder diagnosis 9.5 (8.9–10.2) 4.8 (4.3–5.2) 228.21 <.001
Psychotropic medication 19.2 (18.3–20.2) 18.1 (16.9–19.2) 5.33 .02
Visit to psychiatrist 4.0 (3.5–4.5) 0.9 (0.75–1.2) 233.76 <.001
Psychotherapy 2.3 (1.9–2.7) 0.6 (0.49–0.84) 57.65 <.001
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counterparts did (6.7% vs 8.9%, chi-square = 10.65,
P = .001). Otherwise, psychotropic visits did not vary across
age groups according to race and ethnicity or geography.
For older adult visits with a psychotropic medication
prescribed, just 4.4% of visits were to a psychiatrist, com-
pared with 17.1% for younger adults (chi-square = 175.13,
P < .001). Older adults had a mental health diagnosis at
19.3% of psychotropic visits, versus 36.8% for younger
adults (chi-square = 191.16, P < .001). Depression and
anxiety were the most common diagnoses at psychotropic
visits for both age groups. For both age groups, approxi-
mately half of the psychotropic visits involved anxiolytics
(50.3% for younger adults, 50.8% for older adults; chi-
square = 0.22, P = .64). Figure 2 presents medication visits
on a per capita basis according to medication type. Older
adults had nearly double the rates of antidepressant and
anxiolytic visits, with rates of mood stabilizer and antipsy-
chotic use similar to those of younger adults.
Visits to Psychiatrists
For older adults, women accounted for 67.8% of psychia-
trist visits, an even larger percentage than for younger
adults (60.1%, chi-square = 4.67, P = .03), whereas older
non-Hispanic black adults accounted for fewer visits than
their younger counterparts (3.3% vs 8.8%, chi-
square = 12.38, P < .001). Psychiatrist visits were the only
type of mental health visit with a difference according to
geographic region; a larger percentage occurred in the
northeast for older adults than younger (38.8% vs 29.3%,
chi-square = 4.21, P = .04).
Older adults seeing a psychiatrist were more likely to
have depression and dementia than younger adults and less
likely to have bipolar disorder, substance use, or an anxi-
ety disorder than younger adults.
Psychotherapy Visits
The sex balance of psychotherapy visits was not statisti-
cally significantly different between age groups. Older non-
Hispanic white adults accounted for a larger percentage of
psychotherapy visits than younger non-Hispanic white
adults (89.4% vs 83.2%, chi-square = 4.18, P = .04).
For older adults, primary care providers provided
20.3% of the psychotherapy visits, double the 9.6% of
such visits to younger adults (chi-square = 4.42, P = .03).
The majority of older adult psychotherapy visits were for
a depression diagnosis (54.2%) than of younger adult psy-
chotherapy visits (44.8%) (chi-square = 4.03, P = .04),
with a smaller share of visits than for younger adults for
substance use or anxiety disorders.
DISCUSSION
Prior work has described psychotropic use and psychother-
apy in general practice and specialty psychiatric settings,
although these analyses generally consider the adult popu-
lation overall or compare youth with adults.25–28 A recent,
broad overview of office-based mental health treatment
considered children, adolescents, and adults; again, treat-
ment of older adults was not considered separately.20
Treatment of older adults with mental disorders merits
additional specific attention, because they often have more
comorbid medical problems, are sensitive to psychotropic
medication side effects, have greater potential for poly-
pharmacy-related adverse events, and will be the fastest
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growing segment of the population over the coming
decades.11,29–32 These specific treatment-related concerns
can only be addressed when paired with knowledge regard-
ing where and what manner of treatment currently occurs.
To the knowledge of the authors of the current study,
these are the first analyses to broadly consider whether
and how the provision of outpatient mental health care
varies between younger and older adults as a proportion
of all care provided and on a per capita basis. Visits result-
ing in a mental disorder diagnosis accounted for 4.8% of
all older adult office-based visits, approximately half the
9.5% for younger adults. On a per capita basis, the num-
ber of visits with a mental disorder diagnosis was equiva-
lent between the two age groups, although the rate of
psychiatrist and psychotherapy visits for older adults was
lower, and psychotropic use was far higher. The older
adult psychotropic visit rate of 121.4 found in the current
study is nearly double the 65.9 reported previously as the
adult population rate in an analysis of the same data.20
The high rate of anxiolytic visits is particularly troubling
in light of recent evidence associating benzodiazepine use
with development of dementia.33,34
This work highlights the large role of nonpsychiatrist
providers in the provision of mental health care in general
and for older adults in particular. The findings suggest that
defining mental health care as encounters with a psychia-
trist or other mental health professional does not accu-
rately reflect where people with mental disorder diagnoses
are seen and receive pharmacotherapy or psychotherapy.
Fewer than 1% of all ambulatory physician encounters for
older adults are to psychiatrists, and psychiatrists account
for just 4.4% of visits including psychotropic use by older
adults. Primary care providers account for 20.3% of older
adult psychotherapy visits, in comparison with 9.6% of
such visits for younger adults. It is encouraging that pri-
mary care providers are employing psychotherapy,
although this may suggest a lack of access to psychiatrists
because of provider shortage or psychiatrists’ significantly
lower rate of accepting Medicare.18 Unfortunately, the sur-
vey does not provide information about the nature of psy-
chotherapy provided.
Considering the clinical and demographic characteris-
tics of four visit categories, several trends emerge. First,
the sex imbalance for older adults with mental disorder
diagnoses and treatment is generally consistent with, if not
worse than, that found in the younger adult population.
Older women accounted for a larger share of visits with a
mental disorder diagnosis and to a psychiatrist than youn-
ger women. Although men have a shorter life expectancy,
longevity differences alone cannot account for the sex gap
in mental health diagnoses and treatments in older adults.
Older non-Hispanic black adults accounted for a smaller
share of psychotropic visits and visits to psychiatrists than
their younger counterparts, whereas older non-Hispanic
white adults accounted for more psychotherapy visits. The
rate of visits with mental disorder diagnoses between age
groups did not vary according to race and ethnicity. The
lower use of psychotropic medication may reflect treat-
ment preferences of non-Hispanic black individuals,35
although the finding that older nonwhite adult did not
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Figure 2. Annual population-based visit rates and 95% confidence intervals according to age group for psychotropic visits
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account for more psychotherapy visits than their younger
counterparts my suggest difficulty accessing this type of
treatment.
This work has several limitations. Because NAMCS is
a nationally representative survey of outpatient visits, indi-
vidual-level clinical assessments are not available. It may
be that the high rate of psychotropic prescribing for older
adults is clinically appropriate and that the lower rates for
adults and youth represent undertreatment, although with-
out clinical assessments, such conclusions cannot be made.
Visit diagnoses are limited to three, which means that
mental disorders may be underreported (e.g., generalized
anxiety disorder is item 4 on the problem list and is left
off the survey instrument). This underreporting would be
more likely for older adults as they have more medical
conditions than adults or youth,11 so it is likely that the
visit estimate for mental disorders in older adults in partic-
ular is an underestimate. In addition, it is possible that
some portion of the psychotropic medication use was for a
nonpsychiatric indication such as pain or insomnia,
although given the lack of clinical assessment for these
individuals and the limited list of diagnoses, it is difficult
to make inferences about potentially off-label use with this
data source.
For the first time, these findings present data that
allow direct comparison for older adults relative to youn-
ger adults for office-based mental health visits nationally.
As such, the findings suggest that patterns of care for older
adults are distinct from those for younger adults. Although
visits with a mental disorder diagnosis for older adults
account for approximately half the proportion of such vis-
its for younger adults, psychotropic use is similar, whereas
psychiatrist and psychotherapy visits account for a much
smaller share of total outpatient care. When converted to
a per-population basis, the psychotropic visit rate is far
higher for older adults, demonstrating the extent to which
these medications permeate outpatient office-based care.
Given the financial and time constraints on clinical
care and training, these analyses provide data that health
systems can use as they shepherd resources in the manner
that best serves patient need. The workforce challenges in
psychiatry are long-standing, and these findings demon-
strate the limited role that psychiatrists play in the delivery
of mental health care to older adults. In addition, this
work highlights the pervasiveness of psychotropic use in
the outpatient care of older adults, heightening concern
about the potential appropriateness of use.8,9,36 There is
tremendous need to develop and implement systems of
care that can serve people where they are and where they
wish to be seen;15,37 for older adults, this means outside of
specialty mental health care. It is hoped that new Medi-
care-led initiatives in bundled payment and population-
based care will make implementation of models such as
collaborative care more financially viable.38,39 Regardless,
it is critical that nonpsychiatric providers receive more
training in and support for the management of mental dis-
orders in their clinical practices.
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APPENDIX
Table A1. Psychotropic Drugs Reported in the 2007–2010 National Ambulatory Medical Care Survey
Antidepressants Anxiolytics Antipsychotics Mood Stabilizers
Amitriptyline Alprazolam Chlorpromazine Carbamazepine
Amoxapine Buspirone Fluphenazine Lamotrigine
Bupropion Butabarbital Haloperidol Lithium
Citalopram Butalbital Loxapine Valproate/divalproex
Clomipramine Chloral hydrate Molindone
Doxepin Chlordiazepoxide Perphenazine Stimulants
Duloxetine Clonazepam Pimozide Methylphenidate
Escitalopram Clorazepate Prochlorperazine Dexmethylphenidate
Fluoxetine Diazepam Thioridazine Amphetamine
Fluvoxamine Diphenhydramine Thiothixene Dextroamphetamine
Imipramine Doxepin Trifluoperazine Pemoline
Maprotiline Doxylamine Second Generation: Atomoxetine
Mirtazapine Estazolam Aripiprazole
Nefazodone Eszopiclone Clozapine
Nortriptyline Flurazepam Olanzapine
Paroxetine Hydroxyzine Paliperidone
Phenelzine Lorazepam Quetiapine
Protriptyline Meprobamate Risperidone
Selegiline Midazolam Ziprasidone
Sertraline Oxazepam
Tranylcypromine Pentobarbital
Trazodone Phenobarbital
Venlafaxine Prazepam
Pyrilamine
Ramelteon
Temazepam
Triazolam
Tybamate
Zaleplon
Zolpidem
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